ERBB2 and breast cancer: Each liposomal formulation could efficiently deliver the siRNA against the HER2/neu oncogene in the SKBR-3 BC cells in the presence of serum, as indicated by the downregulation of HER2/neu at the mRNA level (p < 0.001).